Schonfeld Strategic Advisors’s KalVista Pharmaceuticals KALV Stock Holding History

Schonfeld Strategic Advisors’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.35M	Buy	315,537 +9,657	+3%	+$156K	0.04%	424
2025 Q4	$4.94M	Sell	305,880 -140,492	-31%	-$1.86M	0.02%	546
2025 Q3	$5.44M	Buy	446,372 +301,090	+207%	+$4.16M	0.03%	556
2025 Q2	$1.64M	Sell	145,282 -436,464	-75%	-$5.34M	0.01%	1083
2025 Q1	$6.71M	Buy	+581,746	New	+$5.94M	0.04%	439
2024 Q2	–	Sell	-12,800	Closed	-$152K	–	2361
2024 Q1	$152K	Buy	+12,800	New	+$171K	﹤0.01%	1808
2019 Q4	–	Sell	-40,600	Closed	-$471K	–	1386
2019 Q3	$471K	Sell	40,600 -65,800	-62%	-$1.06M	0.01%	662
2019 Q2	$2.36M	Buy	106,400 +95,400	+867%	+$2.24M	0.08%	260
2019 Q1	$315K	Buy	+11,000	New	+$238K	0.01%	821

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Schonfeld Strategic Advisors's KALV Position: Q1 2026 in Review

Schonfeld Strategic Advisors increased its KalVista Pharmaceuticals (KALV) stake by 3.2% in Q1 2026, buying an estimated $156K and bringing the position to 315,537 shares worth $6.35M. The position accounts for 0.04% of the portfolio, ranked #424.

Schonfeld Strategic Advisors first reported a position in KALV in Q1 2019 and has held it in 9 quarters since. The position peaked at $6.71M in Q1 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Schonfeld Strategic Advisors held 315,537 shares of KalVista Pharmaceuticals worth $6.35M as of Q1 2026.
Schonfeld Strategic Advisors bought 9,657 KalVista Pharmaceuticals shares in Q1 2026, an estimated $156K.
KalVista Pharmaceuticals made up 0.04% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #424 holding.
Schonfeld Strategic Advisors first reported a position in KalVista Pharmaceuticals in Q1 2019 and has held it in 9 quarters since.
Schonfeld Strategic Advisors's KalVista Pharmaceuticals position peaked at $6.71M in Q1 2025.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.